765952-41-8

Upstream product

• 67-56-1 methanol 
• 35186-98-2 7-hydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid 
• 66-02-4 3,5-diiodotyrosine 
• 160080-87-5 6,8-diiodo-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 910122-67-7 7-Hydroxy-(3S)-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-tert-butyl ester 3-methyl ester 
• 537-24-6 3,5-dibromo-DL-tyrosine 
• 556-02-5 ?Tyr 

Downstream Products

• 765952-42-9 methyl 7-phenylethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 765952-47-4 7-phenylethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 765952-48-5 ethyl 3-methoxycarbonyl-7-phenylethyl-1,2,3,4-tetrahydroisoquinoline-2-ethanoate 
• 864237-02-5 7-hydroxy-isoquinoline-3-carboxylic acid methyl ester 
• 864236-90-8 C₂₁H₁₈F₄N₄O₂ 

Relevant academic research and scientific papers

Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents

Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145 cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising in vitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.

Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors

RAF kinase plays a critical role in the RAF-MEK-ERK signaling pathway and inhibitors of RAF could be of use for the treatment of various cancer types. We have designed potent RAF-1 inhibitors bearing novel bicyclic heterocycles as key structural elements for the interaction with the hinge region. In both series exploration of the SAR was focussed on the substitution of the phenyl ring, which binds to the induced fit pocket. Overall, it was confirmed that incorporation of lipophilic substituents was needed for potent Raf inhibition and a number of potent analogues were obtained.

ISOQUINOLINE DERIVATIVES

The present invention relates to isoquinoline derivatives of formula (I), the use of the compounds of formula (I), as inhibitors of one or more kinases, the use of the compounds of formula (I), for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Synthesis of 7-phenylethoxy-1,2,3,4-tetrahydroiso- quinoline derivatives

Synthesis of 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives is described, from diiodotyrosine, using a Pictet-Spengler reaction and further O-alkylation of the aromatic ring providing compounds (1) and (2).